<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PHENTOLAMINE MESYLATE</span><br/>(fen-tole'a-meen)<br/><span class="topboxtradename">Regitine, </span><span class="topboxtradename">Rogitine <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha-adrenergic antagonist (blocking agent), sympatholytic</span><br/><b>Prototype: </b>Prazosin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Alpha-adrenergic blocking agent structurally related to tolazoline but with more potent blocking effects. Competitively blocks
         alpha-adrenergic receptors, but action is transient and incomplete. Prevents hypertension resulting from elevated levels of
         circulating epinephrine or norepinephrine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Causes vasodilation and decreases general vascular resistance and pulmonary arterial pressure, primarily by direct action
         on vascular smooth muscle. Through stimulation of beta-adrenergic receptors, produces positive inotropic and chronotropic
         cardiac effects and increases cardiac output.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Diagnosis of pheochromocytoma and to prevent or control hypertensive episodes prior to or during pheochromocytomectomy.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Prevention of dermal necrosis and sloughing following IV administration or extravasation of norepinephrine.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>MI (previous or present), coronary artery disease. Safety during pregnancy (category C) or lactation is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Gastritis, peptic ulcer.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">To Prevent Hypertensive Episode during Surgery</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 25 mg as needed<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 1 mg or 0.1 mg/kg (max: 5 mg/dose)<br/><br/><span class="indicationtitle">To Test for Pheochromocytoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 5 mg<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 0.1 mg/kg<br/><br/><span class="indicationtitle">To Prevent Necrosis from Norepinephrine Infusions</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 10 mg added to each liter of IV fluid containing norepinephrine<br/><br/><span class="indicationtitle">To Treat Catecholamine Extravasation</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">Intradermal</span> 510 mg diluted in 10 mL of normal saline injected into affected area within 12 h of extravasation<br/><span class="rdage">Neonate:</span> <span class="rdroute">Intradermal</span> 2.55 mg diluted in 10 mL of normal saline injected into affected area within 12 h of extravasation (max: dose 0.1 mg/kg
               or 2.5 mg total)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: Place patient in supine position when receiving drug parenterally. Monitor BP and pulse q2min until stabilized.
         		
      </p><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute 5 mg vial with 1 mL of sterile water for injection.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute as for IM. May be further diluted with up to 10 mL of sterile water. Use immediately.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 60 sec.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Weakness, dizziness, flushing, <span class="speceff-common">orthostatic hypotension.</span>
<span class="typehead">GI:</span>
<span class="speceff-common">Abdominal pain, nausea, vomiting, diarrhea, exacerbation of peptic ulcer.</span>
<span class="typehead">CV:</span>
<span class="speceff-common">Acute and prolonged hypotension, tachycardia, anginal pain,</span> cardiac arrhythmias, <span class="speceff-life">MI</span>, cerebrovascular spasm, <span class="speceff-life">shock-like state</span>. <span class="typehead">Special Senses:</span> Nasal stuffiness, conjunctival infection. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> may antagonize BP raising effects of <b>epinephrine,</b>
<b>ephedrine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 2 min IV; 1520 min IM. <span class="typehead"> Duration:</span> 1015 min IV; 34 h IM. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 19 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Test for pheochromocytoma: (1) Withhold medications not deemed absolutely essential for at least 24 h, preferably 4872
            h; antihypertensive agents withheld until BP returns to pretreatment level (rauwolfia drugs withdrawn at least 4 wk prior
            to testing). (2) Keep patient at rest in supine position throughout test, preferably in quiet darkened room. (3) Take BP q10min
            for at least 30 min; when BP stabilizes, (4) IV administration: Record BP immediately after injection and at 30-sec intervals
            for first 3 min; then at 1-min intervals for next 7 min. IM administration: BP determinations at 5-min intervals for 3045
            min.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid sudden changes in position, particularly from reclining to upright posture and dangle legs and exercise ankles and toes
            for a few minutes before standing to walk.
         </li>
<li>Lie down or sit down in head-low position immediately if light-headed or dizzy.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>